Get the Stockscreener App
3.19
0.00%
0.00
After Hours:
3.19
Black Diamond Therapeutics Inc stock is traded at $3.19, with a volume of 203.65K.
It is up +0.00% in the last 24 hours and up +40.53% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$3.19
Open:
$3.165
24h Volume:
203.65K
Relative Volume:
0.18
Market Cap:
$181.39M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.6968
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+4.93%
1M Performance:
+40.53%
6M Performance:
+27.60%
1Y Performance:
-48.63%
1-Day Range:
$3.16
$3.23
1-Week Range:
$3.02
$3.315
52-Week Range:
$1.195
$6.75
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
3.19 | 181.39M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
What analysts say about Black Diamond Therapeutics Inc. stockGame-changing capital returns - Autocar Professional
Is Black Diamond Therapeutics Inc. a good long term investmentUnstoppable profit momentum - Autocar Professional
Black Diamond Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com
Why Black Diamond Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Forecasting Tools - Newser
What drives Black Diamond Therapeutics Inc. stock priceMarket-leading capital gains - Autocar Professional
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise - MSN
why edgewise therapeutics inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
Black Diamond Therapeutics discloses EGFR inhibitors for cancer - BioWorld MedTech
How Black Diamond Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
What makes Black Diamond Therapeutics Inc. stock price move sharplyGroup Only Stock Signals - Newser
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of “Buy” from Analysts - Defense World
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) dropped from Russell 2500 Index - MarketScreener
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Value Index - MarketScreener
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Holdings Boosted by Bank of America Corp DE - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Rating of “Buy” from Analysts - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Wall Street Zen - Defense World
Black Diamond’s 2025 Annual Stockholders Meeting Highlights - TipRanks
Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside - Seeking Alpha
Wellington Management Group LLP Grows Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Squarepoint Ops LLC Buys 72,688 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded to Hold Rating by Wall Street Zen - Defense World
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Nuveen Asset Management LLC - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Purchased by Millennium Management LLC - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Northern Trust Corp - Defense World
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewswire
17,317 Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Bought by D. E. Shaw & Co. Inc. - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) & Fresh Tracks Therapeutics (NASDAQ:FRTX) Critical Comparison - Defense World
Brokerages Set Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Price Target at $14.60 - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) Raised to Buy at Wall Street Zen - Defense World
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):